KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis.
Tanja Limberger, Michaela Schlederer, Karolina Trachtová, Ines Garces de Los Fayos Alonso, Jiaye Yang, Sandra Högler, Christina Sternberg, Vojtech Bystry, Jan Oppelt, Boris Tichý, Margit Schmeidl, Petra Kodajova, Anton Jäger, Heidi A Neubauer, Monika Oberhuber, Belinda S Schmalzbauer, Sarka Pospisilova, Helmut Dolznig, Wolfgang Wadsak, Zoran Culig, Suzanne D Turner, Gerda Egger, Sabine Lagger, Lukas Kenner
Molecular cancer 2022 Mar 30Frequent truncation mutations of the histone lysine N-methyltransferase KMT2C have been detected by whole exome sequencing studies in various cancers, including malignancies of the prostate. However, the biological consequences of these alterations in prostate cancer have not yet been elucidated. To investigate the functional effects of these mutations, we deleted the C-terminal catalytic core motif of Kmt2c specifically in mouse prostate epithelium. We analysed the effect of Kmt2c SET domain deletion in a Pten-deficient PCa mouse model in vivo and of truncation mutations of KMT2C in a large number of prostate cancer patients. We show here for the first time that impaired KMT2C methyltransferase activity drives proliferation and PIN formation and, when combined with loss of the tumour suppressor PTEN, triggers loss of senescence, metastatic dissemination and dramatically reduces life expectancy. In Kmt2c-mutated tumours we show enrichment of proliferative MYC gene signatures and loss of expression of the cell cycle repressor p16INK4A. In addition, we observe a striking reduction in disease-free survival of patients with KMT2C-mutated prostate cancer. We identified truncating events of KMT2C as drivers of proliferation and PIN formation. Loss of PTEN and KMT2C in prostate cancer results in loss of senescence, metastatic dissemination and reduced life expectancy. Our data demonstrate the prognostic significance of KMT2C mutation status in prostate cancer patients. Inhibition of the MYC signalling axis may be a viable treatment option for patients with KMT2C truncations and therefore poor prognosis. © 2022. The Author(s).
Citation
Tanja Limberger, Michaela Schlederer, Karolina Trachtová, Ines Garces de Los Fayos Alonso, Jiaye Yang, Sandra Högler, Christina Sternberg, Vojtech Bystry, Jan Oppelt, Boris Tichý, Margit Schmeidl, Petra Kodajova, Anton Jäger, Heidi A Neubauer, Monika Oberhuber, Belinda S Schmalzbauer, Sarka Pospisilova, Helmut Dolznig, Wolfgang Wadsak, Zoran Culig, Suzanne D Turner, Gerda Egger, Sabine Lagger, Lukas Kenner. KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis. Molecular cancer. 2022 Mar 30;21(1):89
Mesh Tags
Substances
PMID: 35354467
View Full Text
